[1]VISAN, IOANA. New ligand for LAG-3[J]. Nature reviews neuroscience,2019,20(2)：111.[2]WENJIE ZHAI, XIUMAN ZHOU, HONGFEI WANG, et al. A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8 + T cell responses[J]. 药学学报(英文版),2020,10(6)：1047-1060.[3]钟雪锋,WANG TONGMIN. LAG-3 在肿瘤免疫治疗中的研究进展[J]. 重庆医学,2022,51(22)：3943-3947.[4]XU,F., LIU,J., LIU,D., et al. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses[J]. Cancer research： The official organ of the American Association for Cancer Research, Inc,2014,74(13)：3418-3428[5]CAMISASCHI,C., DEFILIPPO,A., BERETTA,V., et al. Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions： Involvement of LAG-3[J]. The Journal of Investigative Dermatology,2014,134(7)：1893-1902.
